Quest Diagnostics
About: Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Employees: 56,000
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
123% more first-time investments, than exits
New positions opened: 138 | Existing positions closed: 62
15% more capital invested
Capital invested by funds: $14.9B [Q4 2024] → $17.2B (+$2.24B) [Q1 2025]
7% more funds holding
Funds holding: 881 [Q4 2024] → 939 (+58) [Q1 2025]
2.82% more ownership
Funds ownership: 88.62% [Q4 2024] → 91.44% (+2.82%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
5% less repeat investments, than reductions
Existing positions increased: 311 | Existing positions reduced: 328
39% less call options, than puts
Call options by funds: $83.5M | Put options by funds: $136M
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$180
0%
upside
Avg. target
$190
6%
upside
High target
$200
11%
upside
8 analyst ratings
3 positive
38%
5 neutral
63%
0 negative
0%
JP Morgan Lisa Gill | 5%upside $190 | Neutral Maintained | 6 May 2025 |
Piper Sandler David Westenberg | 11%upside $200 | Neutral Maintained | 28 Apr 2025 |
Truist Securities David Macdonald | 5%upside $190 | Hold Maintained | 23 Apr 2025 |
Barclays Stephanie Davis | 3%upside $185 | Equal-Weight Maintained | 23 Apr 2025 |
Evercore ISI Group Elizabeth Anderson | 0%downside $180 | In-Line Maintained | 23 Apr 2025 |
Financial journalist opinion
Based on 7 articles about DGX published over the past 30 days
Neutral
PRNewsWire
4 days ago
Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology
SECAUCUS, N.J. , June 10, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) designed to improve the assessment of elevated risk of cancer in individuals who would benefit from medically appropriate cancer screenings.
Positive
Zacks Investment Research
1 week ago
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
2 weeks ago
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick?
With women's health increasingly becoming a global priority, investors are actively targeting companies operating in this space to boost their portfolios. Research and Markets projects the women's health diagnostics market to expand at a compound annual rate of 9.25% through 2030, driven by technological advancements, increasing healthcare expenditures, and initiatives for early detection of women-specific conditions like reproductive health issues, breast cancer, osteoporosis and more.
Positive
Zacks Investment Research
3 weeks ago
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?
DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.
Neutral
PRNewsWire
3 weeks ago
More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals
Quest's second "Know Your Health" survey explores Americans' perceptions and priorities on their well-being in 2025 Nearly one-third of Americans say their doctors/HCPs do not take the time to discuss preventive care and wellness with them; More than half of millennials, Gen Z cite barriers to accessing medical care SECAUCUS, N.J. , May 20, 2025 /PRNewswire/ -- questhealth.com, the consumer-initiated testing platform from Quest Diagnostics (NYSE: DGX), one of the nation's leading providers of diagnostic information services, today revealed the results of its second "Know Your Health" survey, conducted online by The Harris Poll among nearly 2,100 U.S. adults.
Neutral
PRNewsWire
4 weeks ago
Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference
SECAUCUS, N.J. , May 16, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a presentation at the William Blair 45th Annual Growth Stock Conference in Chicago on Tuesday, June 3, 2025, at 11:00 a.m.
Positive
Zacks Investment Research
4 weeks ago
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
1 month ago
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Neutral
PRNewsWire
1 month ago
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J. , May 14, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on July 21, 2025 to shareholders of record of Quest Diagnostics common stock on July 7, 2025.
Positive
Zacks Investment Research
1 month ago
Should You Continue to Retain DGX Stock in Your Portfolio?
Quest Diagnostics continues to stay on investors' radars due to its robust Advanced Diagnostics offerings and strength in acquisitions.
Charts implemented using Lightweight Charts™